Kronos Bio Performance
| KRONDelisted Stock | USD 0.88 0.00 0.00% |
The company secures a Beta (Market Risk) of -0.46, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Kronos Bio are expected to decrease at a much lower rate. During the bear market, Kronos Bio is likely to outperform the market. Kronos Bio right now secures a risk of 0.0%. Please verify Kronos Bio maximum drawdown, as well as the relationship between the expected short fall and day median price , to decide if Kronos Bio will be following its current price movements.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Kronos Bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Kronos Bio is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Kronos |
Kronos Bio Relative Risk vs. Return Landscape
If you would invest 88.00 in Kronos Bio on October 7, 2025 and sell it today you would earn a total of 0.00 from holding Kronos Bio or generate 0.0% return on investment over 90 days. Kronos Bio is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Kronos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Kronos Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kronos Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kronos Bio, and traders can use it to determine the average amount a Kronos Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| KRON |
Based on monthly moving average Kronos Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kronos Bio by adding Kronos Bio to a well-diversified portfolio.
Kronos Bio Fundamentals Growth
Kronos Stock prices reflect investors' perceptions of the future prospects and financial health of Kronos Bio, and Kronos Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kronos Stock performance.
| Return On Equity | -0.59 | |||
| Return On Asset | -0.22 | |||
| Operating Margin | (3.42) % | |||
| Current Valuation | (21.99 M) | |||
| Shares Outstanding | 60.97 M | |||
| Price To Book | 0.67 X | |||
| Price To Sales | 5.84 X | |||
| Revenue | 9.85 M | |||
| EBITDA | (61.72 M) | |||
| Cash And Equivalents | 267.89 M | |||
| Cash Per Share | 4.72 X | |||
| Total Debt | 24.9 M | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 1.31 X | |||
| Cash Flow From Operations | (65.44 M) | |||
| Earnings Per Share | (1.07) X | |||
| Total Asset | 124.36 M | |||
| Retained Earnings | (594.94 M) | |||
About Kronos Bio Performance
By examining Kronos Bio's fundamental ratios, stakeholders can obtain critical insights into Kronos Bio's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Kronos Bio is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company was incorporated in 2017 and is headquartered in San Mateo, California. Kronos Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.Things to note about Kronos Bio performance evaluation
Checking the ongoing alerts about Kronos Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kronos Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kronos Bio is not yet fully synchronised with the market data | |
| Kronos Bio has some characteristics of a very speculative penny stock | |
| Kronos Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 9.85 M. Net Loss for the year was (86.08 M) with profit before overhead, payroll, taxes, and interest of 9.19 M. | |
| Kronos Bio currently holds about 267.89 M in cash with (65.44 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 24.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Kronos Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kronos Bio's stock is overvalued or undervalued compared to its peers.
- Examining Kronos Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kronos Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kronos Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kronos Bio's stock. These opinions can provide insight into Kronos Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Other Consideration for investing in Kronos Stock
If you are still planning to invest in Kronos Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kronos Bio's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |